MedTrace Logo

A Clinical Study of Novel Pneumococcal Vaccine V118C in Children (V118C-002)

NCT07300267 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 210

Last updated 2026-04-17

No results posted yet for this study

Summary

Researchers are looking for new vaccines to prevent pneumococcal disease, which is any infection in the lungs or other parts of the body that is caused by a type of bacteria called Streptococcus pneumoniae. V118C is a new vaccine designed to help prevent disease from Streptococcus pneumoniae bacteria.

This study will look at V118C in toddlers and infants. The goal of the study is to learn how safe V118C is for children and how well they tolerate it.

Conditions

  • Pneumococcal Infection

Interventions

BIOLOGICAL

V118C (Stage 1)

IM administration of V118C

BIOLOGICAL

V118C (Stage 2)

IM administration of V118C

BIOLOGICAL

PCV20 (Stage 1)

IM administration of PCV20

BIOLOGICAL

PCV20 (Stage 2)

IM administration of PCV20

Sponsors & Collaborators

Principal Investigators

  • Medical Director · Merck Sharp & Dohme LLC

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
2 Months
Max Age
15 Months
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-01-13
Primary Completion
2028-10-24
Completion
2029-05-25
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07300267 on ClinicalTrials.gov